Knight Therapeutics

Global Pricing Scrutiny And Latin American Risks Will Erode Margins

AnalystLowTarget

Not Invested

Consensus Narrative from 7 Analysts

Published

31 Aug 25

AnalystLowTarget's Fair Value

CA$6.15

4.7% overvalued

31 Aug

CA$6.44

14.2%

-0.9%

14.2%

-0.9%

Edit anytime before Aug 31 10:43 PM. Then post Updates to your followers.

Author's Valuation

CA$6.2

4.7% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

CA$6.2

4.7% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

8.37%

Pharma revenue growth rate

0.59%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

5.97%

Calculation

CA$25.33m

Earnings '28

27.74x

PE Ratio '28

CA$702.54m

Market Cap '28

CA$702.54m

Market Cap '28

96.28m

No. shares '28

CA$7.30

Share Price '28

CA$7.30 Share Price '28

Discounted to 2025 @ 5.97% p.a.

CA$6.13

Fair Value '25